U.S. court preliminary injunction significantly alleviates WuXi AppTec’s 1260H policy risk

Overview

This report comments on the latest developments in WuXi AppTec’s lawsuit against the U.S. Department of Defense’s 1260H list designation. The company initiated legal proceedings on June 11, 2026, and applied for a preliminary injunction on June 29; after a hearing on July 22, the court granted the application on August 7. Morgan Stanley believes this ruling significantly alleviates the U.S. policy risk facing the company and helps the market refocus on its business fundamentals.

Core views

The court’s 35-page opinion questioned several core bases for the U.S. Department of Defense’s designation of WuXi AppTec: first, the determination that the company is indirectly owned by or affiliated with Chinese state-owned assets, defense industry regulators, or the military may have procedural and factual defects; second, the purported 5.32% shareholding was a misreading, with the actual investment only about US$200,000, representing approximately 0.001% of the company’s equity; third, the company’s participation in related hospital research only reflected its role as a third-party laboratory supplier processing samples and was insufficient to prove an affiliation with the military. Because inclusion on the 1260H list is a necessary but not sufficient condition for inclusion on Biosecure-related lists, the preliminary injunction correspondingly reduces subsequent listing risk. However, the target price is close to the current share price, leaving limited short-term absolute price upside.

Analysis framework

The report combines factual determinations in litigation documents with disputes under the Administrative Procedure Act to assess the transmission impact on Biosecure-related policy risk after the 1260H designation is overturned or suspended; for valuation, it is based on A-share discounted cash flow results and converts the H-share target price using an HKD:RMB rate of 1.10.

Methodology notes

• Event and policy analysisLegal ruling impact analysis

  Assess the continuing validity of the 1260H designation and its potential impact on the company’s operations based on the preliminary injunction and the court’s judgments on facts and administrative procedure.

  The court preliminarily found that parts of the U.S. Department of Defense’s ownership and affiliation rationale may have clear defects, and therefore temporarily suspended the direct adverse consequences of the designation. The preliminary injunction is not a final judgment, and the outcome of subsequent merits litigation still needs to be tracked.

• Policy transmission analysisList inclusion condition analysis

  Analyze the conditional relationship between the 1260H list and Biosecure-related watch lists.

  The report points out that inclusion on the 1260H list is a necessary but not sufficient condition for inclusion on Biosecure-related lists, so the preliminary injunction reduces the probability that WuXi AppTec will subsequently be included on related lists.

• Company valuationDiscounted cash flow model

  Estimate a company’s intrinsic value by forecasting future cash flows and discounting them by the cost of capital.

  The A-share base case uses a 10% weighted average cost of capital and a 4% perpetual growth rate; the H-share target price is derived from the A-share target price using an HKD:RMB exchange rate of 1.10.

Asset mapping & comparison

Structured mapping from thesis to named assets (strengths, weaknesses, peers, risks).

• WuXi AppTec Co Ltd (2359.HK)

  The primary covered stock in the report; the preliminary injunction directly alleviates its U.S. policy risk.

  Strengths

  Policy overhang has significantly declined; demand from multinational pharmaceutical companies for R&D and manufacturing outsourcing is expected to continue rising; artificial intelligence is accelerating the generation of new drug targets and lead compounds, which may increase demand for wet-lab services; higher capacity utilization is expected to drive margin expansion.

  Weaknesses

  The HK$193.00 target price is only slightly above the HK$192.30 closing price, leaving limited short-term absolute upside; valuation remains sensitive to long-term growth and discount-rate assumptions.

  Comparison

  The H-share target price is converted from the A-share valuation using an HKD:RMB rate of 1.10, and shares the same fundamentals and major policy risks as the A-shares.

  Risks

  Reversal of the final judicial outcome, renewed inclusion on relevant U.S. policy lists, deterioration in China-U.S. relations, lower-than-expected end-market sales for important commercial contracts, and volatility in VC/PE financing.

• WuXi AppTec Co Ltd (603259.SS)

  The A-share listed security corresponding to the H-shares and also the underlying valuation basis for the H-share target price.

  Strengths

  The discounted cash flow valuation can directly reflect the value of long-term cash flow growth, outsourcing demand, and utilization improvement.

  Weaknesses

  Sensitive to the 10% weighted average cost of capital and 4% perpetual growth rate, while facing the same geopolitical and business execution risks as the H-shares.

  Comparison

  The report uses the A-share discounted cash flow value as the basis and then derives the H-share target price through exchange-rate assumptions; prices of the two share classes may also be affected by differences in market liquidity, exchange rates, and investor structure.

  Risks

  Changes in China-U.S. relations, lower-than-expected end-market sales, cancellation or delay of customer projects, volatility in VC/PE financing, and lower-than-expected margin improvement.

Key data

• Date court granted preliminary injunction2026-08-07The preliminary injunction temporarily removes the direct adverse consequences of the 1260H designation.
• RatingOverweightMorgan Stanley expects the risk-adjusted total return over the next 12 to 18 months to outperform the average of its industry coverage.
• Industry viewPositiveThe original report uses Attractive.
• H-share target priceHK$193.00Converted from the A-share discounted cash flow valuation using an HKD:RMB rate of 1.10.
• H-share closing priceHK$192.30As of August 7, 2026.
• Target-price upsideapproximately 0.4%Calculated based on the HK$193.00 target price and HK$192.30 closing price.
• 52-week price rangeHK$96.70–193.00The current share price is near the upper end of the range listed in the report.
• Related investment amountapproximately US$200,000The report states that this investment represents only about 0.001% of WuXi AppTec’s equity, not a 5.32% ownership stake in the company.
• Discount rate10%The weighted average cost of capital used in the A-share discounted cash flow base case.
• Perpetual growth rate4%Assumption used in the A-share discounted cash flow base case.

Impact & implications

The preliminary injunction reduces the risk that the 1260H designation will immediately affect WuXi AppTec’s U.S. business and customer relationships, and also weakens the policy transmission chain for the company’s further inclusion on Biosecure-related lists. A lower risk discount supports valuation recovery and shifts market focus back to multinational pharmaceutical companies’ outsourcing demand, growth in new drug targets and lead compounds driven by artificial intelligence, and margin improvement from higher capacity utilization. However, because the H-share price is already close to the target price, further short-term upside depends more on the final judicial outcome, updates to policy lists, or upward revisions to earnings forecasts.

Risks

• The preliminary injunction is not a final judgment, and adverse changes may still occur in subsequent merits litigation or administrative procedures.
• Relevant U.S. agencies may continue to restrict the company through other legal or policy channels, and uncertainty remains around the final updates to Biosecure-related lists.
• Deterioration in China-U.S. relations may affect customer decisions, business cooperation, and the valuation risk premium.
• End-market sales of drugs corresponding to important commercial contracts may fall short of expectations, including impacts from loss of market exclusivity.
• Volatility in VC/PE financing may weaken R&D spending and order demand from early-stage biotechnology customers.
• Outsourcing demand, capacity utilization, or margin expansion may fall short of expectations.
• The target price is already close to the current share price, leaving limited short-term risk-reward space without further fundamental upgrades.
• Morgan Stanley disclosed that it holds at least 1% of one class of common equity securities of WuXi AppTec Co Ltd and has had investment banking and other service relationships with the company in the past 12 months; investors should pay attention to potential conflicts of interest.

What to watch

• Subsequent procedures and final judgment in the litigation related to the 1260H designation.
• Whether the U.S. Department of Defense files an appeal, supplements evidence, or makes a new administrative determination.
• Updates to Biosecure-related watch lists in December 2026 and whether WuXi AppTec is included.
• Changes in orders, renewals, project transfers, and customer concentration among the company’s U.S. customers.
• Changes in the proportion of R&D and manufacturing outsourcing by multinational pharmaceutical companies.
• Whether AI-driven growth in new drug targets and lead compounds can translate into wet-lab service orders.
• Improvements in capacity utilization, margins, and free cash flow.
• Subsequent adjustments to A-share and H-share target prices, exchange-rate assumptions, and earnings forecasts.